Age-related treatment patterns for stage I NSCLC in three European countries.


Journal

Journal of geriatric oncology
ISSN: 1879-4076
Titre abrégé: J Geriatr Oncol
Pays: Netherlands
ID NLM: 101534770

Informations de publication

Date de publication:
11 2021
Historique:
received: 04 01 2021
revised: 09 04 2021
accepted: 06 05 2021
pubmed: 18 5 2021
medline: 15 12 2021
entrez: 17 5 2021
Statut: ppublish

Résumé

Surgery is the preferred treatment for patients with early-stage non-small cell lung cancer (NSCLC) while stereotactic body radiation therapy (SBRT) may be applied in patients with major comorbidity or high age. We evaluated the association between age and treatment utilization for early-stage NSCLC in patients diagnosed in 2015-2016 in three European countries. Information was retrieved from population-based registries in England, Norway and the Netherlands. Treatment patterns and two-year overall survival rates for 105,124 patients with clinical stage I were analysed by age-group. Surgical resection rates were higher in Norway (55%) and England (53%) than in the Netherlands (47%), and decreased with increasing age. SBRT use was highest in the Netherlands (41%), followed by Norway (29%) and England (12%). In the Netherlands, SBRT was the prevailing treatment in patients aged 70 years or older. In octogenarians, the proportion not receiving curative intent treatment was 53% in England, versus 35% in Norway and 22% in the Netherlands. Two-year survival rates were better for surgery than for SBRT and slightly better in Norway. In patients aged 70 years or older, the proportion not receiving any curative treatment remains substantial, and differs significantly between countries. Measures to address these disparities are needed.

Identifiants

pubmed: 33994330
pii: S1879-4068(21)00113-2
doi: 10.1016/j.jgo.2021.05.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1214-1219

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Dr. Senan reports grants from Varian Medical Systems, grants from ViewRay Inc., grants and personal fees from AstraZeneca, outside the submitted work. Other authors had nothing to disclose.

Auteurs

Ronald A M Damhuis (RAM)

Department of Research and Development, Association of Comprehensive Cancer Centres, Utrecht, Netherlands. Electronic address: R.Damhuis@iknl.nl.

Suresh Senan (S)

Department of Radiation Oncology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam, Netherlands.

Aamir Khakwani (A)

Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK.

Susan Harden (S)

Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Ȧslaug Helland (Ȧ)

Department of Oncology, Oslo University Hospital, University of Oslo, Clinical Medicine, Oslo, Norway.

Trond-Eirik Strand (TE)

Department of Registration, Cancer Registry of Norway, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH